Asia Pacific Apheresis Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 0.74 Billion |
| Market Size (2029) | USD 1.22 Billion |
| CAGR (2024 - 2029) | 10.57 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Asia Pacific Apheresis Market Analysis
The Asia Pacific Apheresis Market size is estimated at USD 0.74 billion in 2024, and is expected to reach USD 1.22 billion by 2029, growing at a CAGR of 10.57% during the forecast period (2024-2029).
The major factors attributing to the growth of the Asia Pacific apheresis market are increasing diseases burden, rise in demand for blood components and associated safety and technological advancement in the development of new apheresis techniques. However, the factors such as high capital investment and cost associated with apheresis procedures is expected to restrain the market.
Apheresis has now become a popular mode of treatment for multiple complex immune disorders and there has been a remarkable change in the scenario pertaining to therapeutic apheresis in Asia-Pacific. With the increasing number of diseases and accident cases, along with technological advancements, the market studied is expected to experience a boost during the forecast period. Additionally, the rising number of government initiatives, blood donation camps, and increasing awareness about healthcare are the factors responsible for the growth of the market studied. Apheresis technology is expensive. It is also technically and medically demanding.
Asia Pacific Apheresis Market Trends
This section covers the major market trends shaping the APAC Apheresis Market according to our research experts:
Neurological Disorders is Expected to Grow with High CAGR in the Indication Segment
The pattern of neurologic diseases in Asia is largely similar to that in the western countries, with cerebrovascular diseases, headache, and epileptic seizures being the most common complaints.
Disease features that are specific to Asia include a high proportion of strokes among the youth, mostly from premature atherosclerosis, a high prevalence of intracranial vs extracranial diseases, the relative commonality of neuromyelitis optica and the optic-spinal form of multiple sclerosis (MS), and high incidences of sex-linked dystonia and Parkinson’s disease. Plasma exchange is one of the well-established therapeutic procedures that is usually used in many neurological autoimmune disorders. It is thought that the effects of plasma exchange occur through the elimination of pathognomonic inflammatory mediators, including autoantibodies, complement components, and cytokines. Most of the neurological disease treatments are benefited with therapeutic apheresis, and these effects most likely occur through the removal of harmful pathogenic autoantibodies and associated inflammatory mediators.
Asia Pacific Apheresis Industry Overview
The Asia Pacific aphersis market is moderately competitive and consists of several major players. In terms of market share, few major players are currently dominate the apheresis market. With the increasing prevalence of diseases in the Asia pacific region and the usage of apheresis is expected to rise, thereby few other players are also expected into the market. Some of the major players of the market are Asahi Kasei Corporation, B. Braun Melsungen AG, Cerus Corporation, Kaneka Corporation and Terumo Corporation are among others.
Asia Pacific Apheresis Market Leaders
-
Asahi Kasei Corporation
-
B. Braun Melsungen AG
-
Cerus Corporation
-
Kaneka Corporation
-
Terumo Corporation
*Disclaimer: Major Players sorted in no particular order
Asia Pacific Apheresis Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Deliverables
- 1.2 Study Assumptions
- 1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Disease Burden in Asia
- 4.2.2 Rise in Demand for Blood Components and Associated Safety
- 4.2.3 Technological Advancement in the Development of New Apheresis Techniques
-
4.3 Market Restraints
- 4.3.1 High Capital Investment and Cost Associated with Apheresis Procedures
- 4.3.2 Risk of Blood Contamination
-
4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 By Product
- 5.1.1 Devices
- 5.1.2 Disposables
-
5.2 By Indication
- 5.2.1 Renal Disorders
- 5.2.2 Hematological Disorders
- 5.2.3 Neurological Disorders
- 5.2.4 Autoimmune Disorders
- 5.2.5 Other Indications
-
5.3 By Procedure
- 5.3.1 Plasmapheresis
- 5.3.2 Plateletpheresis
- 5.3.3 Erythrocytapheresis
- 5.3.4 Leukapheresis
- 5.3.5 Other Procedures
-
5.4 Geography
- 5.4.1 China
- 5.4.2 Japan
- 5.4.3 India
- 5.4.4 Australia
- 5.4.5 South Korea
- 5.4.6 Rest of Asia Pacific
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Asahi Kasei Corporation
- 6.1.2 B. Braun Melsungen AG
- 6.1.3 Cerus Corporation
- 6.1.4 Kaneka Corporation
- 6.1.5 Terumo Corporation
- 6.1.6 Fresenius SE & Co. KGaA
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityAsia Pacific Apheresis Industry Segmentation
Apheresis is a medical technique, where the blood of an individual, either a donor or patient, is passed through an apparatus that separates a particular constituent and returns the rest of the blood to the circulatory system. This is an extracorporeal therapy.
| By Product | Devices |
| Disposables | |
| By Indication | Renal Disorders |
| Hematological Disorders | |
| Neurological Disorders | |
| Autoimmune Disorders | |
| Other Indications | |
| By Procedure | Plasmapheresis |
| Plateletpheresis | |
| Erythrocytapheresis | |
| Leukapheresis | |
| Other Procedures | |
| Geography | China |
| Japan | |
| India | |
| Australia | |
| South Korea | |
| Rest of Asia Pacific |
Asia Pacific Apheresis Market Research FAQs
How big is the Asia Pacific Apheresis Market?
The Asia Pacific Apheresis Market size is expected to reach USD 0.74 billion in 2024 and grow at a CAGR of 10.57% to reach USD 1.22 billion by 2029.
What is the current Asia Pacific Apheresis Market size?
In 2024, the Asia Pacific Apheresis Market size is expected to reach USD 0.74 billion.
Who are the key players in Asia Pacific Apheresis Market?
Asahi Kasei Corporation, B. Braun Melsungen AG, Cerus Corporation, Kaneka Corporation and Terumo Corporation are the major companies operating in the Asia Pacific Apheresis Market.
What years does this Asia Pacific Apheresis Market cover, and what was the market size in 2023?
In 2023, the Asia Pacific Apheresis Market size was estimated at USD 0.67 billion. The report covers the Asia Pacific Apheresis Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Asia Pacific Apheresis Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
APAC Apheresis Industry Report
Statistics for the 2024 APAC Apheresis market share, size and revenue growth rate, created by Mordor Intelligenceā¢ Industry Reports. APAC Apheresis analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
